Dupuytrens

Scharp-Lacy focuses on addressing early-stage disease progression and later-stage therapies through inflammatory response mitigation and improved tissue vascularity. Our research focuses on both clinical and nonclinical products as well as therapeutic modalities. Our research has led to the discovery of core actives that help to slow disease progression and increase lost mobility.